Abstract
analysis using CHADS2 values for creating 3 categories of patients [6] (CHADS2 score of 0 to 1; 2; 3 to 6). Despite the progressive increase in events with increasing score, the effect of dabigatran was consistent. This demonstrates that the observed benefit with this drug is independent of the baseline CHADS2 value, leading us also to hypothesize that the same may be applicable to apixaban and rivaroxaban. Therefore, in face of these data, the need for an adjustment of the observed hazard ratio to the basal CHADS2 score as far as the metaanalysis endpoints are concerned seems unnecessary. The only exception to this observation may be intracranial bleeding. The authors of this manuscript have certified that they comply with the Principles of Ethical Publishing in the International Journal of Cardiology [7]. References
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
